CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

Circulating MicroRNAs and Monocyte-Platelet Aggregate Formation in Acute Coronary Syndrome Risk Factors Associated With Major Cardiovascular Events 1 Year After Acute Myocardial Infarction Comparison of the Preventive Efficacy of Rosuvastatin Versus Atorvastatin in Post-Contrast Acute Kidney Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention Editor's Choice- Impact of immediate multivessel percutaneous coronary intervention versus culprit lesion intervention on 1-year outcome in patients with acute myocardial infarction complicated by cardiogenic shock: Results of the randomised IABP-SHOCK II trial Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial High-Sensitivity Troponin and The Application of Risk Stratification Thresholds in Patients with Suspected Acute Coronary Syndrome The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction

Original Research2015 Jul 10;4(7). pii: e001906.

JOURNAL:J Am Heart Assoc. Article Link

National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study

Zhang L, Jiang L; China PEACE Collaborative Group. Keywords: acute myocardial infarction; clopidogrel; quality of care

ABSTRACT


BACKGROUND - Early clopidogrel administration to patients with acute myocardial infarction (AMI) has been demonstrated to improve outcomes in a large Chinese trial. However, patterns of use of clopidogrel for patients with AMI in China are unknown.


METHODS AND RESULTS - From a nationally representative sample of AMI patients from 2006 and 2011, we identified 11 944 eligible patients for clopidogrel therapy and measured early clopidogrel use, defined as initiation within 24 hours of hospital admission. Among the patients eligible for clopidogrel, the weighted rate of early clopidogrel therapy increased from 45.7% in 2006 to 79.8% in 2011 (P<0.001). In 2006 and 2011, there was significant variation in early clopidogrel use by region, ranging from 1.5% to 58.0% in 2006 (P<0.001) and 48.7% to 87.7% in 2011 (P<0.001). While early use of clopidogrel was uniformly high in urban hospitals in 2011 (median 89.3%; interquartile range: 80.1% to 94.5%), there was marked heterogeneity among rural hospitals (median 50.0%; interquartile range: 11.5% to 84.4%). Patients without reperfusion therapy and those admitted to rural hospitals were less likely to be treated with clopidogrel.


CONCLUSIONS - Although the use of early clopidogrel therapy in patients with AMI has increased substantially in China, there is notable wide variation across hospitals, with much less adoption in rural hospitals. Quality improvement initiatives are needed to increase consistency of early clopidogrel use for patients with AMI.


CLINICAL TRIAL REGISTRATION - URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01624883.



© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.